Consecutive early stage breast cancer patients who are treated according to the national guidelines. Observation over 11 years.

Breast Cancer

Breast Cancer is 100 x more frequent in female than in male

Breast Concervative or Meastectomy

Helse Stavanger HF

Helse Bergen HF

Prospective Breast Cancer Biobanking

Prospective Breast Cancer Biobanking Project

Time from surgery to relapse of breast cancer

Time from surgery until death of any cause

VAS=visual analogue scale; range 0 to 100 mm; higher score is worse fatigue)

percent of patients on disability pension i.e not participation in work

The precent of patients still on tamoxifen after 5 years and 10 years follow-up

The precent of patients still on taromatase inhibitor after 2 years and 5 years follow-up

Percent infiltration of inflammation cells (higer score means more inflammation)

Haavard Soiland

Consultant Breast Cancer Surgery / Professor dr. med.

Helse-Bergen HF

bevacizumab and chemotherapy given every 21 day untill disease progression or unacceptable toxicity

Metastatic Triple Negative Breast Cancer

Safety Issues

Efficacy

-bevacizumab 15m.g/ kg + carboplatin 450m.g + paclitaxel 175m.g/m2 D1 /21 Day until disease progression or un acceptable toxicity .

Bevacizumab

Clinical Oncology Departement Assuit University Hospital

Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer

Phase 2 Study to Evaluate the Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer

the length of time during and after the treatment that a patient lives with the disease but it does not get worse

length of time from the date of diagnosis to the time of death or lost follow up.

the length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive.

Hebat-Allah Mahmoud Bakri Ahmed

assisstant lecturer

Assiut University

Patients receive cediranib maleate PO QD on day 1. Patients undergoing FMISO scan also receive olaparib PO BID beginning the day after the second FMISO scan and the rest of the patients receive olaparib PO BID beginning day 4 of cycle 1. Cycles repeat every 28 days (35 days for cycle 1) in the absence of disease progression or unacceptable toxicity.

Metastatic Pancreatic Adenocarcinoma

Pancreatic Ductal Adenocarcinoma

Stage III Breast Cancer AJCC v7

Stage III Lung Non-Small Cell Cancer AJCC v7

Stage III Lung Small Cell Carcinoma AJCC v7

Stage III Pancreatic Cancer AJCC v6 and v7

Stage IIIA Breast Cancer AJCC v7

Stage IIIA Lung Non-Small Cell Cancer AJCC v7

Stage IIIA Lung Small Cell Carcinoma AJCC v7

Stage IIIB Breast Cancer AJCC v7

Stage IIIB Lung Non-Small Cell Cancer AJCC v7

Stage IIIB Lung Small Cell Carcinoma AJCC v7

Stage IIIC Breast Cancer AJCC v7

Stage IV Breast Cancer AJCC v6 and v7

Stage IV Lung Non-Small Cell Cancer AJCC v7

Stage IV Lung Small Cell Carcinoma AJCC v7

Stage IV Pancreatic Cancer AJCC v6 and v7

Triple-Negative Breast Carcinoma

Unresectable Pancreatic Carcinoma

18F-Fluoromisonidazole

Cediranib

Cediranib Maleate

Laboratory Biomarker Analysis

Olaparib

Positron Emission Tomography

UC San Diego Moores Cancer Center

University of California Davis Comprehensive Cancer Center

University of California San Diego

UCSF Medical Center-Mount Zion

Smilow Cancer Center/Yale-New Haven Hospital

Yale University

Moffitt Cancer Center-International Plaza

Moffitt Cancer Center

Dana-Farber Cancer Institute

Wayne State University/Karmanos Cancer Institute

Weisberg Cancer Treatment Center

Vanderbilt University/Ingram Cancer Center

M D Anderson Cancer Center

Virginia Commonwealth University/Massey Cancer Center

BCCA-Vancouver Cancer Centre

University Health Network-Princess Margaret Hospital

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Measured by Response Evaluation Criteria in Solid Tumors version 1.1. The exact two-sided 95% confidence interval for the objective response rate will be reported.

Graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Descriptive statistics, including means, standard deviations, and ranges for continuous parameters, as well as percentages and frequencies for categorical parameters, will be presented. Adverse medical events will be tabulated. National Cancer Institute toxicity grade 3 and grade 4 laboratory abnormalities will be listed.

Estimated using the Kaplan-Meier method with the 95% confidence intervals. Thomas and Grunkemeier confidence interval will be reported. The possible risk factors will be compared for survival with log-rank test. For multivariate analysis, the proportional hazards Cox model will be applied to investigate potential prognostic factors, such as age and stage of disease on the survival data. The adjusted p-values of the hazard ratios and the adjusted 95% confidence interval will be reported.

In the first 20 endpoint-evaluable patients with non-small cell lung cancer and 20 endpoint-evaluable patients with triple negative breast cancer, the exploratory analyses will be done using Fisher's exact tests, Mann-Whitney U tests or McNemar's test depending on the type of data observed.

Measured by 18F-fluoromisonidazole positron emission tomography/computed tomography scans (non-small cell lung cancer). For the pre- and post-cediranib therapy outcome analysis, paired t- test or Wilcoxon signed-rank test will be applied for the continuous variables.

triple negative breast neoplasms/hypoxie

Prospective Breast Cancer Biobanking

Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

La base de données d'herbes médicinales la plus complète soutenue par la science